500 Boylston Street, Boston, MA 02116 617-419-4700
Return to Results
This study is being performed to determine if the drug that is being researched, Nesiritide (Natrecor), as compared to placebo, plus the usual treatment for acute decompensated heart failure (standard of care) helps improve breathing, reduce hospital readmissions, and helps patients live longer.
Description: Regardless of which group patients are randomized to, all patients will receive the usual treatment for acute decompensated heart failure (standard of care), in addition to the study drug. The study drug will be given intravenously for up to 7 days, and will be adjusted according to the patient’s condition. During the infusion, the patient will be assessed frequently, and this may include daily blood work, a physical exam, frequent blood pressure measurements, pulse rate, respiratory rate, weight measurement, urine sampling and questioning about symptoms and breathing. Most or all of these assessments will be repeated after discharge on day 30, in the clinic, and by phone 6 months following discharge.
Patients with heart failure will be considered for the trial.
Sponsor: Scios, Inc.
Phase: Phase 4
Trial ID: 00413
Not Accepting Healthy Volunteers